Introduction
============

Recently, the Centers for Disease Control and Prevention in the United States reported a 54.5% increase from the 1999 rate of 16.5 deaths per 100,000 patients with Alzheimer's disease (AD) ([@B60]), which is one of the most common progressive neurodegenerative diseases and is characterized by the interaction of both genetic and environmental factors, resulting in memory dysfunction and behavioral changes ([@B25]). In 2013, the number of older people in China was almost 200 million, and the proportion of the population that was aged 65 years and older increased to 14.3% ([@B59]). The World Alzheimer Report 2015 updated the estimates of the global prevalence, China is the region with the most people living with dementia (9.5 million), and the prevalence for the population aged 60 and older is 6.19% ([@B49]; [@B71]). Currently, disease-modifying therapy and an ideal diagnostic tool for AD are largely lacking, severely influencing patients' quality of life and leading to a heavy financial burden for patients' families.

Preclinical Alzheimer's, the newly defined disease stage, demonstrates that brain changes are progressively initiated 10 to 20 years before the onset of dementia symptoms ([@B5]). Thus, identifying biomarkers for preclinical Alzheimer's contributed to the early recognition and prediction of the progression of AD. Notably, the diagnostic tool should be inexpensive, easy to perform, and non-invasive ([@B64]). Recent scientific evidence suggests some potential diagnostic biomarkers such as β-amyloid (Aβ) ([@B9]) and tau ([@B42]) accumulation in cerebrospinal fluid (CSF), Pittsburgh compound B positron emission tomography (PiB-PET) ([@B37]), and peripheral blood protein ([@B73]) and microRNA (miRNA) expression ([@B20]), among which blood-derived biomarkers have been extensively studied due to their less invasive source ([@B8]; [@B32]; [@B45]). Although previous studies have demonstrated plasma protein profiles may be a valuable diagnostic biomarker for the early stage of AD, the findings have not been widely replicated in different races ([@B31]; [@B57]).

Therefore, based on these findings, the present study focuses on plasma protein differences in healthy individuals and patients with AD, exploring a specific protein panel as a potential diagnostic biomarker for AD patients in Han Chinese.

Materials and Methods {#s1}
=====================

Study Population
----------------

We recruited 1,105 older people aged 56--95 years from 2015 to 2017. Eventually, 98 AD patients diagnosed with the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) were recruited from Wuxi and Shanghai Mental Health Centers. The cognitive function of these participants was assessed by two skilled professional psychiatrists using the Mini-Mental State Examination (MMSE). The absence of depression was documented on the basis of a score of 10 or less on the Hamilton Rating Scale for Depression (HAMD). A brain computed tomography (CT) or magnetic resonance imaging (MRI) scan excluded other structural brain diseases, and neurologic examination showed no significant abnormalities. A total of 101 elderly healthy subjects were recruited through advertisements, and their demographic characteristics were carefully recorded.

Exclusion Criteria
------------------

Patients with any dementia other than AD, such as vascular dementia, dementia with Lewy bodies, frontotemporal dementia or Parkinson's disease, were excluded. In addition, a history of stroke or cerebrovascular disease, bone marrow transplantation, major psychiatric disorder, and a history of alcohol or drug abuse were causes for exclusion from the study.

Study Design
------------

Plasma samples from AD and elderly healthy controls from Shanghai and Wuxi in China were obtained. In total, we examined plasma samples from 199 subjects: 98 with AD and 101 elderly controls with no dementia. Multiple protein differences were explored using Luminex xMAP technology. Statistical analysis was performed to assess the relative importance of these protein biomarkers for the diagnosis of AD.

This study was approved by the Ethics Committees of the Wuxi Health Mental Center. Either patients or their guardians signed informed consent. If participants failed to fill out the consent form more than twice, their guardians were asked to fill out the consent form on the patients' behalf.

Luminex Assays
--------------

Luminex xMAP technology (Austin, TX, United States) uses a solid phase approach to analyze multiple proteins. In brief, the xMAP technology is a flow cytometric-based platform that uses microspheres inserted with a ratio of two different fluorescent dyes. In theory, up to 100 differently colored beads can be generated with a theoretical multiplex capacity of up to 100 assays per well of a 96-well plate. The capture antibody is covalently coupled to the bead, and immunoassays are run under standard sandwich immunoassay formats ([@B27]).

The Luminex kits were obtained from Millipore (Billerica, MA, United States) and the assays were performed according to the manufacturer's instructions ([@B58]). Eleven Milliplex MAP multiplex panels covering 50 proteins (96-well plate format; EMD Millipore) were utilized: cat.\# HCYTOMAG-60K (7-plex); cat.\# HIGFBMAG-53K (2-plex); cat.\# HMHEMAG-34K (2-plex); cat.\# HMMP2MAG-55K (2-plex); cat.\# HNDG1MAG-36K (7-plex); cat.\# HNDG2MAG-36K (6-plex); cat.\# HNDG3MAG-36K (10-plex); cat.\# HND2MAG-39K (3-plex); cat.\# HND3MAG-39K (7-plex); cat.\# SKINMAG-50K (1-plex); and cat.\# HKI6MAG-99K (3-plex). Properly diluted plasma samples were incubated with the antibody-coupled microspheres and then with biotinylated detection antibody before the addition of streptavidin-phycoerythrin. The captured bead complexes were measured with a FLEXMAP 3D system (Luminex Corporation, Austin, TX, United States) using the following instrument settings: events/bead, 50; sample size, 50 μL; discriminator gate, 8000--15,000. The raw data (mean fluorescence intensity) were collected and further processed for calculating protein concentration ([@B74]; [@B2]).

Data Processing
---------------

Quality checks (QC) based on standard curve linearity, intraassay coefficient of variation, interassay coefficient of variation for reference sample, and percentage of missing data were performed to examine the performance of each assay followed by measuring median fluorescent intensity (MFI) using xPONENT 5.1 (Luminex Corporation). This was further exported into Milliplex Analyst 5.1 (VigeneTech, United States) to calculate protein concentrations by a five-parameter logistic fit. Afterward, all analytes were subjected to the statistical analysis.

Statistical Analysis
--------------------

All analysis results were expressed as the mean ± SD. Statistical analyses were performed using the Statistical Package for the Social Sciences software version 20.0 (SPSS Inc., Chicago, IL, United States). Pearson's chi-square test was used to compare gender between control subjects and AD patients. All 50 blood protein levels were non-normally distributed, and subsequently underwent ln or square root transformation. The results of transforming the variables are displayed in the table. An independent-sample *t*-test was used to compare age, education and MMSE score and overall protein differences between control subjects and AD patients. Discriminant analysis was performed to assess the relative importance of these biomarkers in classifying AD and controls. In the case of the stepwise method, Wilk's lambda method was used to build the prediction model. The discriminant analysis used a partial *F*-test (F to enter 3.84; F to remove 2.71) and a stepwise method (maximum number of steps = 64) to sequentially incorporate the set of 32 significant variables into the canonical discriminant function. To check the reliability of our analysis, leave-one-out cross-validation was used. Receiver operating characteristic (ROC) analyses were conducted under the non-parametric distribution assumption for standard error of area to determine the performance of the models for discriminating AD from controls.

Results
=======

Study Participants
------------------

The demographic and clinical characteristics of healthy controls and AD patients are presented in Table [1](#T1){ref-type="table"}. Briefly, the mean age of AD patients and their healthy counterparts were 78.76 ± 8.06 and 78.33 ± 7.30 years, respectively. No significant difference was found in age, gender or education between these two groups. As expected, patients with AD had significantly lower MMSE scores than healthy controls (*P* = 0.000).

###### 

Characteristics of AD patients and control subjects.

                      Controls (*n* = 101)   AD (*n* = 98)   χ^2^/*t*-test   *P*-value
  ------------------- ---------------------- --------------- --------------- -----------
  Gender (M/F)        35/66                  34/64           0.000           0.995
  Age (years)         78.33 ± 7.30           78.76 ± 8.06    -0.393          0.695
  Education (years)   5.77 ± 4.77            5.00 ± 4.37     1.175           0.241
  MMSE score          25.70 ± 2.90           8.62 ± 7.58     20.783          0.000^\*^
                                                                             

Chi-square was used for the gender comparison. Independent-sample t-test was used for age, education, and MMSE score.

∗

P \< 0.05 indicated statistical significance.

Differentially Expressed Protein
--------------------------------

In this study, we applied Luminex assay technology to determine the expression profiles of 50 proteins in the plasma from AD patients and healthy controls. Of the fifty candidates, thirty-two proteins were found to be differentially expressed, with statistical significance between AD patients and healthy controls (*P* \< 0.05) (Table [2](#T2){ref-type="table"}).

###### 

Blood protein levels of AD patients and control subjects.

                                Data conversion   AD (*n* = 98)     Controls (*n* = 101)   *t*-Test   *P*-value
  ----------------------------- ----------------- ----------------- ---------------------- ---------- ---------------
  G-CSF (pg/ml)                 Ln (x+1)          3.510 ± 1.166     3.052 ± 1.097          2.584      0.005^\*\*^
  IL-10 (pg/ml)                 Ln (x+1)          1.039 ± 0.800     0.759 ± 0.730          2.578      0.011^\*^
  MCP (pg/ml)                   Ln (x+1)          1.106 ± 1.715     1.100 ± 1.768          0.026      0.980
  IL-1a (pg/ml)                 Ln (x+1)          2.044 ± 1.567     1.659 ± 1.578          1.726      0.086
  IL-3 (pg/ml)                  Ln (x+1)          0.239 ± 0.276     0.147 ± 0.143          2.953      0.004^\*\*^
  IL-8 (pg/ml)                  Ln (x+1)          1.896 ± 1.260     1.726 ± 1.205          0.972      0.332
  MIP (pg/ml)                   Ln (x+1)          0.511 ± 0.811     0.528 ± 0.825          -0.152     0.880
  IGFBP-2 (ng/ml)               Ln (x+1)          4.933 ± 1.085     4.122 ± 1.090          5.263      0.000^\*\*\*^
  IGFBP-6 (ng/ml)               Ln (x)            6.179 ± 0.461     6.169 ± 0.502          0.137      0.891
  B-2 Microglobulin (ng/ml)     Ln (x)            8.064 ± 0.874     7.529 ± 0.770          4.580      0.000^\*\*\*^
  Clusterin (ng/ml)             SQRT (x)          878.97 ± 162.09   729.87 ± 183.25        6.069      0.000^\*\*\*^
  Cystatin C (ng/ml)            SQRT (x)          30.248 ± 7.670    23.610 ± 8.306         5.852      0.000^\*\*\*^
  PP (pg/ml)                    Ln (x)            4.802 ± 0.971     4.667 ± 0.791          1.084      0.280
  TNFa (pg/ml)                  SQRT (x)          2.778 ± 0.731     2.622 ± 0.724          1.511      0.132
  MMP-2 (pg/ml)                 Ln (x)            12.046 ± 0.286    11.976 ± 0.232         1.882      0.061
  MMP-9 (pg/ml)                 Ln (x)            10.37 ± 0.700     10.55 ± 0.589          -1.927     0.055
  CP (ng/ml)                    SQRT (x)          551.21 ± 229.25   557.25 ± 196.47        -0.200     0.842
  AGP (ng/ml)                   Ln (x)            13.155 ± 1.944    13.475 ± 1.200         -1.394     0.163
  HP (ng/ml)                    SQRT (x)          1434.3 ± 926.7    1714.9 ± 1025.6        -2.023     0.044^\*^
  sSOD1 (ng/ml)                 Ln (x)            5.440 ± 0.656     5.443 ± 0.498          -0.031     0.975
  AGT (ng/ml)                   Ln (x)            4.476 ± 1.993     6.470 ± 1.729          -7.544     0.000^\*\*\*^
  Fetuin A (ng/ml)              SQRT (x)          371.97 ± 45.32    377.39 ± 55.23         -0.755     0.451
  sSOD2 (ng/ml)                 Ln (x)            3.773 ± 0.476     3.640 ± 0.352          2.232      0.027^\*^
  Contactin-1 (ng/ml)           SQRT (x)          11.44 ± 1.982     11.29 ± 1.570          0.592      0.554
  Kallikrein-6 (ng/ml)          SQRT (x)          2.806 ± 0.628     2.555 ± 0.452          3.252      0.001^\*\*^
  OPN (ng/ml)                   SQRT (x)          7.060 ± 1.489     5.874 ± 1.248          6.098      0.000^\*\*\*^
  a2-Macroglobulin (ng/ml)      SQRT (x)          1299.5 ± 304.59   1146.9 ± 329.78        3.388      0.001^\*\*^
  APO A1 (ng/ml)                SQRT (x)          625.61 ± 175.59   609.57 ± 250.79        0.521      0.603
  APO CIII (ng/ml)              SQRT (x)          411.28 ± 113.22   368.82 ± 137.12        2.385      0.018^\*^
  APO E (ng/ml)                 SQRT (x)          289.40 ± 71.73    253.24 ± 90.32         3.133      0.002^\*\*^
  Complement C3 (ng/ml)         SQRT (x)          184.42 ± 76.35    208.99 ± 73.32         -2.331     0.021^\*^
  Prealbumin (ng/ml)            SQRT (x)          457.61 ± 113.94   411.31 ± 128.43        2.687      0.008^\*\*^
  Complement factor H (ng/ml)   SQRT (x)          583.95 ± 115.00   502.41 ± 165.47        4.047      0.000^\*\*\*^
  CRP (ng/ml)                   Ln (x)            9.255 ± 2.643     9.580 ± 1.352          -1.086     0.279
  A1-Antitrypsin (ng/ml)        Ln (x)            7.649 ± 1.340     8.151 ± 1.190          -2.792     0.006^\*\*^
  PEDF (ng/ml)                  SQRT (x)          61.96 ± 23.23     63.61 ± 17.57          -0.565     0.572
  SAP (ng/ml)                   Ln (x)            10.812 ± 2.551    11.656 ± 1.368         -2.921     0.004^\*\*^
  MIP-4 (ng/ml)                 Ln (x)            4.140 ± 0.784     4.011 ± 0.637          1.277      0.203
  Complement C4 (ng/ml)         SQRT (x)          156.81 ± 72.86    116.06 ± 49.76         4.594      0.000^\*\*\*^
  BDNF (pg/ml)                  Ln (x)            8.006 ± 1.219     6.818 ± 0.942          7.705      0.000^\*\*\*^
  Cathepsin D (pg/ml)           SQRT (x)          608.92 ± 178.92   479.43 ± 154.10        5.476      0.000^\*\*\*^
  sICAM-1 (pg/ml)               SQRT (x)          365.19 ± 69.65    300.29 ± 84.30         5.910      0.000^\*\*\*^
  MPO (pg/ml)                   SQRT (x)          12.080 ± 1.491    11.519 ± 1.494         2.649      0.009^\*\*^
  PDGF-AA (pg/ml)               Ln (x)            7.212 ± 0.969     6.322 ± 0.756          7.206      0.000^\*\*\*^
  RANTES (pg/ml)                Ln (x)            10.122 ± 1.025    9.138 ± 1.030          6.751      0.000^\*\*\*^
  NCAM (pg/ml)                  SQRT (x)          608.35 ± 96.051   505.86 ± 126.59        6.446      0.000^\*\*\*^
  PDGF-AB/BB (pg/ml)            Ln (x)            8.270 ± 1.161     7.789 ± 0.621          7.185      0.000^\*\*\*^
  sVCAM-1 (pg/ml)               SQRT (x)          956.61 ± 185.54   778.87 ± 215.38        6.215      0.000^\*\*\*^
  PAI-1 Total (pg/ml)           SQRT (x)          366.67 ± 117.04   331.95 ± 124.71        2.024      0.044^\*^
  HSA (μg/ml)                   SQRT (x)          208.60 ± 40.69    192.74 ± 51.37         2.410      0.017^\*^
                                                                                                      

Significant P-value (

∗

P \< 0.05,

∗∗

P \< 0.01,

∗∗∗

P \< 0.001).

Stepwise Discriminant Function Analysis
---------------------------------------

Afterward, we performed a stepwise discriminant function analysis to further determine how effectively AD patients and healthy controls can be distinguished based on the expressed protein levels and to assess the differential contribution to the diagnosis. Of the 32 significant plasma markers, a feature group of eight most discriminative proteins, including brain-derived neurotrophic factor (BDNF), angiotensinogen (AGT), insulin-like growth factor binding protein 2 (IGFBP-2), osteopontin (OPN), cathepsin D, serum amyloid P component (SAP), complement C4, and prealbumin (transthyretin, TTR), was sorted out by stepwise discriminant analysis (Table [3](#T3){ref-type="table"}, all *P* = 0.00), indicating their potential contributions to diagnosis. To detect whether this 8-protein panel was efficient in differentiating AD from healthy controls, we carried out both original- and cross-validation, correctly classifying 86.7 and 84.7% of the cases, respectively (Table [4](#T4){ref-type="table"}).

###### 

Summary of canonical discriminant analysis (stepwise method).

  Step   Entered variable   Wilk's lambda   Exact F   *P*-value   Standardized coefficients
  ------ ------------------ --------------- --------- ----------- ---------------------------
  1      BDNF               0.768           59.363    0.000       0.355
  2      AGT                0.651           52.431    0.000       -0.459
  3      IGFBP-2            0.557           51.731    0.000       0.395
  4      OPN                0.522           44.492    0.000       0.330
  5      Cathepsin D        0.490           40.134    0.000       0.286
  6      SAP                0.453           38.665    0.000       -0.748
  7      Complement C4      0.410           39.311    0.000       0.549
  8      Prealbumin         0.398           35.967    0.000       0.258
                                                                  

At each step, the variable that minimizes the overall Wilk's lambda is entered: a. Maximum number of steps is 64; b. Minimum partial F to enter is 3.84; c. Maximum partial F to remove is 2.71; d. F level, tolerance, or VIN insufficient for further computation.

###### 

Discriminant classification results^b,c^.

  Clinical diagnosis   Predicted group membership   Total                     
  -------------------- ---------------------------- ------------ ------------ -----
  Original             Controls                     89 (88.1%)   12 (11.9%)   101
                       AD                           13 (13.3%)   85 (86.7%)   98
                       Total                        107          92           199
  Cross-validated^a^   Controls                     87 (86.1%)   14 (13.9%)   101
                       AD                           15 (15.3%)   83 (84.7%)   98
                       Total                        106          93           199
                                                                              

a

Cross validation was performed only for those cases in the analysis. In cross validation, each case is classified by the functions derived from all cases other than that case.

b

86.7% of original grouped cases correctly classified.

c

84.7% of cross-validated grouped cases correctly classified.

The Classification Performance of the 8-Protein Panel
-----------------------------------------------------

Furthermore, we decided the classification performance of the eight-protein panel and each biomarker by calculating the discriminant score (Table [5](#T5){ref-type="table"}) and receiver operating characteristic (ROC) curve (Figure [1](#F1){ref-type="fig"}), resulting in an 87.4% correct classification for AD and control subjects with high sensitivity (86.7%) and specificity (88.1%), which suggested that the combination of these eight differentially expressed plasma proteins produced the most accurate results in a threshold classification.

###### 

Summary of ROC curve analysis.

                       AUC     Sensitivity   Specificity   Correct classification                   
  -------------------- ------- ------------- ------------- ------------------------ ------- ------- -------
  BDNF                 0.776   0.033         0.000         0.711∼0.841              0.704   0.743   72.4%
  AGT                  0.203   0.034         0.000         0.138∼0.269              0.776   0.634   70.4%
  IGFBP-2              0.707   0.037         0.000         0.635∼0.779              0.673   0.634   65.3%
  OPN                  0.739   0.035         0.000         0.671∼0.808              0.643   0.723   68.3%
  Cathepsin D          0.735   0.035         0.000         0.666∼0.804              0.571   0.762   66.8%
  SAP                  0.425   0.041         0.067         0.345∼0.504              0.449   0.634   54.3%
  Complement C4        0.694   0.038         0.000         0.618∼0.769              0.643   0.644   64.3%
  Prealbumin           0.619   0.038         0.004         0.541∼0.697              0.653   0.574   61.3%
  Discriminant Score   0.958   0.012         0.000         0.934∼0.982              0.867   0.881   87.4%
                                                                                                    

a

Under the non-parametric assumption.

b

Null hypothesis: true area = 0.5.

![Receiver-operating characteristic (ROC) curve for the 8-protein panel and each protein.](fnagi-10-00414-g001){#F1}

Discussion
==========

To date, disease-modifying treatments have not been successfully developed for AD. Continuous clinical trials for novel drugs have failed, suggesting early diagnosis and prevention of AD is crucial for postponing the progression of disease effectively. Approximately 500 mL of cerebrospinal fluid (CSF), which is in direct contact with the extracellular space of the brain, is absorbed into the blood daily ([@B16]; [@B15]; [@B26]). Plasma contains multiple biological components, including proteins, peptides, lipids, and metabolites, which also effectively reflect physiological activity and pathology in the central nervous system (CNS). To our knowledge, this is the first study to investigate potential plasma protein biomarkers in the Han Chinese population using a high-throughput multiplexed xMAP Luminex assay. Our present findings suggest that a set of eight plasma proteins (BDNF, AGT, IGFBP-2, OPN, cathepsin D, SAP, complement C4, and TTR) serves as a putative predictor panel for AD diagnosis with high sensitivity and specificity. Importantly, these proteins have been considered to be interesting and potentially significant in AD disease pathology in previous studies ([@B48]; [@B28]; [@B11]; [@B14]; [@B43]; [@B65]; [@B69]; [@B10]).

Recently, blood-derived biomarkers for AD have been widely considered for being relatively painless, inexpensive and having diagnostic accuracy. Using predictive analysis of microarrays, a previous study demonstrated that a panel of 18 plasma proteins (CCL18, CCL15, CCL7, CXCL8, ICAM-1, TRAIL-R4, G-CSF, GDNF, EGF, CCL5, M-CSF, IL-3, IL-1α, TNF-α, PDGF-BB, IL-11, ANG-2, and IGFBP-6) achieved a diagnostic accuracy of 90% in distinguishing AD and mild cognitive impairment (MCI) ([@B50]), which was reported to be unable to distinguish patients with AD from the populations through enough diagnostic precision ([@B7]). In addition, it also failed to reach comparable accuracy in discriminating patients with AD and healthy controls using 16 and 8 plasma proteins derived from this 18-protein panel, respectively ([@B58]; [@B39]), which might be attributed to only three of these 18 plasma proteins being differentially expressed between AD and healthy controls in an independent replication study. Afterward, [@B62] also performed a subsequent study to investigate 26 proteins that had been identified as potential AD biomarkers, including the 18-protein panel reported by [@B50]. Although only two proteins were found to be significantly different between AD and controls, they identified that a 10-protein panel (TTR, CLU, cystatin C, A1AcidG, ICAM-1, CC4, pigment epithelium-derived factor, A1AT, RANTES, and ApoC3) could predict the progression of MCI to AD with high diagnostic accuracy. However, of these proteins, ICAM-1 was a unique protein that overlapped with Ray's study. O'Bryant and colleagues used a panel from RBM to identify a list of 30 biomarkers to detect AD ([@B46], [@B47]).

It is well known that the pathological mechanism of AD is diverse. The fifty proteins selected in the present study, including those proteins that were reported in previous studies, are involved in the various signaling pathways associated with AD, including the immune response ([@B24]), inflammatory ([@B23]; [@B24]) and antioxidant ([@B3]) processes, and metabolism ([@B4]; [@B12]). Of this 8-protein panel, three proteins, CC4, TTR, and IGFBP-2, overlapped with previous studies ([@B6]; [@B66]; [@B40]) and affect immunology, Aβ fibril formation, DNA synthesis, and cell proliferation and death in AD.

The complement system is considered to be highly involved in the inflammatory response as a powerful component of innate immunity, consisting of more than 30 fluid-phase and cell-associated proteins as well as a wide range of specific receptors that interact to trigger the inflammatory response ([@B52]; [@B68]). Recent genome-wide association studies (GWAS) have identified the association of complement receptor 1 with AD ([@B22]; [@B34]; [@B56]; [@B44]). However, whether these complement molecules have any diagnostic value has not been fully elucidated. Elevated levels of complement 3 and 4 (C3 and C4) in cerebrospinal fluid (CSF) were found in AD, compared with MCI, patients ([@B14]). Moreover, increased plasma levels of C4a protein were found in the plasma of AD patients ([@B6]). Consistently, complement C4 was highly expressed in the plasma of AD participants in this study. We further showed that complement C4 had 64.3% accuracy for distinguishing AD from healthy individuals with 64.3% sensitivity and 64.4% specificity, indicating that complement C4 alone was inadequate as a biomarker for AD diagnosis.

Transthyretin (TTR) is a transport protein, also known as prealbumin, which has been found in cerebrospinal fluid (CSF) as an Aβ-binding protein and suppresses the toxicity of oligomers. Thus, the sequester protein, as an efficient inhibitor of Aβ fibril formation, may delay the pathologic progression of AD via the Aβ clearance signaling pathway ([@B10]). A previous study showed that TTR concentration was substantially decreased in the peripheral blood of individuals with aMCI and AD, indicating that a set of sequester proteins, including TTR, can discriminate individuals with mild cognitive decline from healthy controls ([@B66]). In contrast to this result, we found a significant increase in TTR concentration in AD patients when compared with normal controls, which might be attributed to the different ethnic populations revealing a number of influencing factors, such as heredity, environment, and lifestyle.

Among the candidate proteins, IGFBP2 was the one most frequently chosen. IGFBP-2 can influence DNA synthesis, cell proliferation and death, as well as glucose and amino acid uptake in cells by inhibiting IGF functions ([@B30]; [@B51]). Overexpression of IGFBP-2 in mice led to decreased weights of the hippocampus, cerebellum, olfactory bulb, and prefrontal cortex ([@B55]). In addition, IGFBP-2 was also reported to significantly increase in the serum of AD participants ([@B61]; [@B40]), which was consistent with our findings. In addition, other insulin-like growth factors and the corresponding binding proteins were differentially expressed in both the CSF and serum from AD patients ([@B53]), in which the expression of IGF-1 was reduced in serum ([@B67]), while IGF-2 was highly expressed in CSF ([@B1]). However, it has also been reported that serum, instead of CSF of IGF-1 and IGFBP3, was increased in AD ([@B29]), both of which were more closely associated with AD in men than in women ([@B18]). Using a longitudinal case-control study, [@B46] found that serum protein-based biomarkers involving IGFBP-2 protein can be combined with clinical information to accurately classify AD ([@B46]). Subsequently, using the multiplex panel, [@B17] identified an 18-plasma biomarker panel including IGFBP-2 that is useful for the diagnosis of AD ([@B17]). These findings suggested that IGFBP-2 may be a key factor in a panel of protein biomarkers for the diagnosis of AD.

In addition, some proteins on the panel, including SAP, have been associated with hippocampal atrophy and the rate of change and progression to dementia ([@B63]; [@B54]). Importantly, we performed bioinformatics analysis and identified a close and interactive network among these proteins (data not shown), partly supporting the intimate relationship of the 8-protein panel with AD.

It is well known that recent clinical trials for the Aβ clearing strategies have failed ([@B19]; [@B41]). Previous findings showed that 30% of cognitively normal elderly patients show signs of Aβ accumulation and, accordingly, a substantial number of AD patients show no signs of Aβ accumulation ([@B72]). In addition, several conflicting findings were demonstrated when using plasma Aβ peptides as markers for AD, suggesting that Aβ from peripheral blood may not reflect brain Aβ metabolism ([@B13]; [@B21]; [@B33]). Importantly, Aβ can bind to a variety of proteins in blood, resulting in epitope masking and analytical interference ([@B38]). In addition, methodology was also a limitation in the present study. The Milliplex MAP multiplex panels containing Aβ protein can only be used with CSF samples. To ensure the strong consistency of the results, the detection of plasma Aβ levels was not performed using other methods in this study.

Although many studies have identified plasma proteins related to AD \[e.g., BDNF ([@B36]; [@B35])\], complement C4a ([@B6]), IGFBP-2 ([@B40]), TTR ([@B66]), and SAP ([@B70]), these are unlikely to be useful as a diagnostic test when used as single markers due to a lack of sensitivity and specificity. Based on the complexity of the pathogenesis of AD, as a relatively reliable biomarker for the diagnosis of AD, combinations of plasma proteins associated with various biological pathways may be necessary. Of note, accumulating evidence indicates that the replication and validation of results is urgent and important for exploratory studies. Thus, we plan to further validate our findings in a large-scale population that includes AD, MCI, and healthy controls.

The present findings should be interpreted considering some limitations. Since AD overlaps with other dementia forms, such as vascular dementia, frontotemporal dementia, and dementia with Lewy bodies, in the context of pathological traits, whether the same protein panel can accurately reflect their relationship to AD, but not to other dementia diseases, is a very important question. At present, only AD patients and healthy controls were included in this study, and no other dementia subtypes or disease stages were identified. In addition, our results may be influenced by the limited sample size. Moreover, due to the limitation of methodology, we did not detect plasma Aβ levels in the present study. Hence, more extensive studies including a large number of dementia subtypes should be conducted in the future. Furthermore, there are various factors, such as activity, diet, and medications, that can alter plasma protein levels.

Conclusion
==========

Taken together, the present study identified a plasma 8-protein panel including BDNF, AGT, IGFBP-2, OPN, cathepsin D, SAP, complement C4 and TTR that showed the highest determinative score for AD and healthy controls. Thus, these findings suggest that a combination of eight plasma proteins is a valuable diagnostic biomarker for AD in the Chinese population, providing novel insight for the diagnosis of AD.
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